PaxSafe's Mark Talens on why pharma supply chain AI fails before it starts — and the data foundry framework that changes that.
|Articles|March 3, 2015
US Judge Blocks Ranbaxy Launch Bid
Author(s)News Update
March 3, 2015.
Advertisement
Reuters reports that Ranbaxy's bid to reinstate approvals granted for the launch of the first copies of Roche's heartburn drug Nexium and AstraZeneca's antiviral Valcyte has been denied by a US federal judge. Ranbaxy sued FDA in November 2014 for pulling approvals that would have allowed it to launch the copies.
Judge Beryl Howell of the District Court for DC also repoertedly blocked Ranbaxy's call for a preliminary injunction to halt Teva, Endo International, and Dr Reddy's Laboratories from launching copies of the two drugs.
FDA said its earlier decision granting Ranbaxy the approvals was made "in error" as the company's plants were not compliant with the U.S. regulator's manufacturing quality standards.
Source:
Advertisement
Related to this article
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Advertisement
Advertisement
Trending on PharmExec
1
The Bubble You Don’t Know You’re In: A Three-Part Series on The Medical Benefit Bubble
2
EMA Panel Backs Lilly’s Foundayo for Obesity and Type 2 Diabetes in Europe
3
FDA Approves Enspryng (Satralizumab) for Thyroid Eye Disease
4
Pharmaceutical Executive Daily: Gilead Enters $1.87 Billion Collaboration and License Agreement with Vir Biotechnology
5